Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#.
The endothelial cell (EC) receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1, and urokinase-type plasminogen activator receptor (uPAR) and is essential for activation of the kinin system that leads to bradykinin (BK) generation. Of these, gC1qR/p33 constitutes a high affinity site fo...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2011.00058/full |
| _version_ | 1818319020980436992 |
|---|---|
| author | Berhane eGhebrehiwet Jolyon eJesty Sulan eXu Rama eVinayagasundaram Uma eVinayagasundaram Yan eJi Alisa eValentino Kinga H. Hosszu Sally eMathew Kusumam eJoseph Allen P. Kaplan Ellinor I.B. Peerschke |
| author_facet | Berhane eGhebrehiwet Jolyon eJesty Sulan eXu Rama eVinayagasundaram Uma eVinayagasundaram Yan eJi Alisa eValentino Kinga H. Hosszu Sally eMathew Kusumam eJoseph Allen P. Kaplan Ellinor I.B. Peerschke |
| author_sort | Berhane eGhebrehiwet |
| collection | DOAJ |
| description | The endothelial cell (EC) receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1, and urokinase-type plasminogen activator receptor (uPAR) and is essential for activation of the kinin system that leads to bradykinin (BK) generation. Of these, gC1qR/p33 constitutes a high affinity site for HK—the BK precursor—and is therefore critical for the assembly of the kinin-generating cascade. Previous studies have identified a putative HK site within the C-terminal domain (residues 204-218) of gC1qR recognized by mAb 74.5.2. In these studies, we used information from the crystal structure of gC1qR, to engineer several deletion (Δ) mutants and test their ability to bind and/or support BK generation. While deletion of residues 204-218 (gC1qRΔ204-218), showed significantly reduced binding to HK, BK generation was not affected when tested by a sensitive bradykinin immunoassay. In fact, all of the gC1qR deletion mutants supported BK generation with the exception of gC1qRΔ154-162 and a point mutation in which Trp 233 was substituted with Gly. Binding studies also identified the existence of two additional sites at residues 144-162 and 190-202. Moreover, binding of HK to a synthetic peptide 190-202 was inhibited by mAbs 48 and 83, but not by mAb 74.5.2. Since a single residue separates domains 190-202 and 204-218, they may be part of a highly stable HK binding pocket and therefore a potential target for drug design to prevent vascular permeability and inflammation. |
| first_indexed | 2024-12-13T10:02:29Z |
| format | Article |
| id | doaj.art-8dd35afb024c44ccb77518389fe9e1a1 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-13T10:02:29Z |
| publishDate | 2011-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8dd35afb024c44ccb77518389fe9e1a12022-12-21T23:51:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242011-11-01210.3389/fimmu.2011.0005812683Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#.Berhane eGhebrehiwet0Jolyon eJesty1Sulan eXu2Rama eVinayagasundaram3Uma eVinayagasundaram4Yan eJi5Alisa eValentino6Kinga H. Hosszu7Sally eMathew8Kusumam eJoseph9Allen P. Kaplan10Ellinor I.B. Peerschke11Stony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityStony Brook UniversityMedical University of South CarolinaMedical University of South CarolinaMount Sinai School of MedicineThe endothelial cell (EC) receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1, and urokinase-type plasminogen activator receptor (uPAR) and is essential for activation of the kinin system that leads to bradykinin (BK) generation. Of these, gC1qR/p33 constitutes a high affinity site for HK—the BK precursor—and is therefore critical for the assembly of the kinin-generating cascade. Previous studies have identified a putative HK site within the C-terminal domain (residues 204-218) of gC1qR recognized by mAb 74.5.2. In these studies, we used information from the crystal structure of gC1qR, to engineer several deletion (Δ) mutants and test their ability to bind and/or support BK generation. While deletion of residues 204-218 (gC1qRΔ204-218), showed significantly reduced binding to HK, BK generation was not affected when tested by a sensitive bradykinin immunoassay. In fact, all of the gC1qR deletion mutants supported BK generation with the exception of gC1qRΔ154-162 and a point mutation in which Trp 233 was substituted with Gly. Binding studies also identified the existence of two additional sites at residues 144-162 and 190-202. Moreover, binding of HK to a synthetic peptide 190-202 was inhibited by mAbs 48 and 83, but not by mAb 74.5.2. Since a single residue separates domains 190-202 and 204-218, they may be part of a highly stable HK binding pocket and therefore a potential target for drug design to prevent vascular permeability and inflammation.http://journal.frontiersin.org/Journal/10.3389/fimmu.2011.00058/fullBradykininInflammationVascular permeabilitygC1qRkininogen |
| spellingShingle | Berhane eGhebrehiwet Jolyon eJesty Sulan eXu Rama eVinayagasundaram Uma eVinayagasundaram Yan eJi Alisa eValentino Kinga H. Hosszu Sally eMathew Kusumam eJoseph Allen P. Kaplan Ellinor I.B. Peerschke Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. Frontiers in Immunology Bradykinin Inflammation Vascular permeability gC1qR kininogen |
| title | Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. |
| title_full | Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. |
| title_fullStr | Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. |
| title_full_unstemmed | Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. |
| title_short | Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation#. |
| title_sort | structure function studies using deletion mutants identify domains of gc1qr p33 as potential therapeutic targets for vascular permeability and inflammation |
| topic | Bradykinin Inflammation Vascular permeability gC1qR kininogen |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2011.00058/full |
| work_keys_str_mv | AT berhaneeghebrehiwet structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT jolyonejesty structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT sulanexu structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT ramaevinayagasundaram structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT umaevinayagasundaram structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT yaneji structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT alisaevalentino structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT kingahhosszu structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT sallyemathew structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT kusumamejoseph structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT allenpkaplan structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation AT ellinoribpeerschke structurefunctionstudiesusingdeletionmutantsidentifydomainsofgc1qrp33aspotentialtherapeutictargetsforvascularpermeabilityandinflammation |